Results 31 to 40 of about 12,625 (176)

Nirmatrelvir-ritonavir et simvastatine

, 2023
International audienceNirmatrelvir-ritonavir et simvastatine L'association nirmatrelvir-ritonavir est indiquée dans le traitement de la Covid-19 chez les patients adultes qui présentent un risque accru d'évolution vers une forme sévère.
Legeay, Samuel, Faure, Sébastien
core   +1 more source

Nirmatrelvir Plus Ritonavir: First Approval

, 2022
DeclarationsFunding The preparation of this review was not supported by any external funding.Authorship and Conflict of interest During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the ...
Yvette Lamb (6930427)
core   +1 more source

Nirmatrelvir/ritonavir and risk of long COVID symptoms: a retrospective cohort study

Scientific Reports, 2023
We conducted a retrospective cohort study to assess whether treatment with nirmatrelvir/ritonavir was associated with a reduced risk of long COVID. We enrolled 500 adults with confirmed SARS-CoV-2 who were eligible for nirmatrelvir/ritonavir; 250 who ...
Seth Congdon, Zev Narrowe, Nang Yone, Jacob Gunn, Yuting Deng, Priya Nori, Kelsie Cowman, Marjan Islam, Sharon Rikin, Joanna Starrels   +9 more
doaj   +1 more source

MOLNUPIRAVIR DAN NIRMATRELVIR/RITONAVIR SEBAGAI TERAPI ORAL COVID-19

, 2022
COVID-19 merupakan penyakit infeksi yang disebabkan virus SARS-CoV-2 yang dideklarasikan sebagai pandemik global pada tanggal 11 Maret 2020. COVID-19 dapat berakibat fatal hingga menyebabkan kematian, sehingga diperlukan penanganan yang serius. Obat-obat
Raharjo, Sofyan Budi, Angelina, Emanuela
core   +1 more source

A case report of a prolonged decrease in tacrolimus clearance due to co-administration of nirmatrelvir/ritonavir in a lung transplant recipient receiving itraconazole prophylaxis

Journal of Pharmaceutical Health Care and Sciences, 2023
Background Drug-drug interaction management is complex. Nirmatrelvir/ritonavir is a potent cytochrome P450 (CYP) 3A inhibitor and influences pharmacokinetics of co-administered drugs.
Ayumi Tsuzawa, Yoshiki Katada, Keisuke Umemura, Mitsuhiro Sugimoto, Asami Nishikawa, Yu-ki Sato, Yuko Yoshida, Noriaki Kitada, Atsushi Yonezawa, Daisuke Nakajima, Hiroshi Date, Tomohiro Terada   +11 more
doaj   +1 more source

Nirmatrelvir–Ritonavir (Paxlovid) for Mild Coronavirus Disease 2019 (COVID-19) in Pregnancy and Lactation [PDF]

, 2023
Nirmatrelvir-ritonavir (Paxlovid) is recommended to reduce the risk of hospitalization from coronavirus disease 2019 (COVID-19) in pregnancy. Data on use in pregnancy, including prescribing patterns and patient experience (adverse effects, incidence of ...
Prahl, Mary, Yarden Golan, Li, Lin, Golan, Yarden, Lin Li, Lin, Christine, Cassidy, Arianna, Arianna G. Cassidy, Mary K. Prahl, Gaw, Stephanie, Stephanie L. Gaw, Christine Y. Lin   +11 more
core   +1 more source

Nirmatrelvir combined with ritonavir for preventing and treating COVID‐19 [PDF]

, 2022
BACKGROUND: Oral nirmatrelvir/ritonavir (Paxlovid®) aims to avoid severe COVID‐19 in asymptomatic people or those with mild symptoms, thereby decreasing hospitalization and death. Due to its novelty, there are currently few published study results.
Kranke, Peter, Meybohm, Patrick, Peter Kranke, Maria Popp, Metzendorf, Maria Inti, Rebecca Kuehn, Weibel, Stephanie, Reis, Stefanie, Kuehn, Rebecca, Stefanie Reis, Patrick Meybohm, Skoetz, Nicole, Ildiko Gagyor, Gagyor, Ildiko, Stephanie Weibel, Nicole Skoetz, Metzendorf, Maria-Inti, Maria-Inti Metzendorf, Popp, Maria   +18 more
core   +1 more source

Recommendations for the Management of Drug–Drug Interactions Between the COVID‐19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications [PDF]

, 2022
The coronavirus disease 2019 (COVID‐19) antiviral nirmatrelvir/ritonavir (Paxlovid) has been granted authorization or approval in several countries for the treatment of patients with mild to moderate COVID‐19 at high risk of progression to severe disease
Burger, D, Waters, L., Boffito, Marta, Charles Flexner, Anton Pozniak, David J. Back, Flexner, C, Waters, Laura, Back, David J., Gibbons, S., Boyle, Alison, Waters, L, Khoo, Saye, Sara Gibbons, Burger, David, Marzolini, C., Burger, D.M., Marra, Fiona, Marzolini, C, Flexner, C., Khoo, S., Boffito, M., Saye Khoo, Khoo, S, Flexner, Charles, Gibbons, S, Marta Boffito, Daniel R. Kuritzkes, Laura Waters, David Burger, Marzolini, Catia, Marra, F., Kuritzkes, Daniel R., Catia Marzolini, Alison Boyle, Kuritzkes, DR, Back, D.J., Boyle, A., Boffito, M, Back, DJ, Boyle, A, Fiona Marra, Gibbons, Sara, Marra, F, Pozniak, A., Pozniak, A, Kuritzkes, D.R., Pozniak, Anton   +47 more
core   +1 more source

Is Azvudine Comparable to Nirmatrelvir-Ritonavir in Real-World Efficacy and Safety for Hospitalized Patients with COVID-19? A Retrospective Cohort Study

Infectious Diseases and Therapy, 2023
Introduction Azvudine and nirmatrelvir-ritonavir are more extensively used to treat COVID-19 in China due to their earlier approval by the National Medical Products Administration.
Qinqin Zhao, Bei Zheng, Bing Han, Pinpin Feng, Zhongni Xia, Hong Jiang, Yin Ying, Jun Zhu, Cheng Fei, Junlei Xiang, Lingli Shen, Qiliang Luo, Yinhuan Wu, Ayiguzhali Wusiman, Chuanwei Xin, Meiling Zhang, Gonghua Li, Xiang Li   +17 more
doaj   +1 more source

The interaction between nirmatrelvir/ritonavir and sirolimus: a case report of a kidney recipient with renal insufficiency and COVID-19

Journal of International Medical Research
Nirmatrelvir/ritonavir is a novel drug combination authorized by the US Food and Drug Administration for the treatment of coronavirus disease 2019 (COVID-19).
Yinhua Gong, Dan Shen, Jinfang Shi, Ye Jiang, Jie Gao   +4 more
doaj   +1 more source